The Amplatzer muscular VSD occluder was approved by the Food and Drug Administration
in 2007 and is currently the only device approved for VSD closure in the United States. The …

Ventricular septal defects (VSDs) are the most common kind of congenital heart disease
and, if indicated, surgical closure has been accepted as a gold-standard treatment …

Objectives: We sought to report the results of a US registry of device closure of congenital
muscular ventricular septal defects (VSDs) using the new Amplatzer mVSD occluder (AGA …

Transcatheter closure of congenital ventricular septal defect (VSD) using various devices is
gaining acceptance in selected cases of perimembranous and muscular defects, avoiding …

Surgical closure of multiple muscular ventricular septal defects (MVSDs) is associated with
mortality and morbidity; therefore, both surgeons and cardiologists welcome a nonsurgical …

OBJECTIVE: Both surgical management and percutaneous device closure of muscular
ventricular septal defects have drawbacks and limitations. This report describes our initial …

This study reports on experience with transcatheter closure of congenital ventricular septal
defects (VSDs) with Amplatzer septal occluders. From January 2000 to April 2005 …

Percutaneous closure of perimembranous ventricular septal defects (VSDs) has been
feasible, safe, and effective with the new Amplatzer membranous septal occluder. We report …

目的应用国产和进口室间隔缺损(室缺) 封堵器封堵室缺, 通过3~ 6 个月的随访来评价其疗效和
安全性. 方法30 例室缺患者, 男性12 例, 女性18 例, 年龄6~ 42 岁, 体重26~ 77 (45.3±21.4) kg …

Hybrid procedures are becoming increasingly important, especially in the management of
congenital heart lesions for which there are no ideal surgical or interventional options. This …